Bal Pharma Ltd

Bal Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Bal Pharma Ltd

₹ 86.2 -1.01%
05 Jun - close price
balpharma.com BSE: 524824 NSE: BALPHARMA
About

Incorporated in 1987, Bal Pharma Ltd does manufacturing and selling of pharmaceutical products and related services[1]

Key Points

Business Overview:[1]
BALPL is a fully integrated pharmaceuticals company specialising in Bulk Drugs, Prescription Drugs, Generics, Pharma intermediates, and Ayurvedic products. Company focuses on therapeutic areas viz. Anti-diabetes, Anti-histamine, Anti-inflammatory, Acne Treatment, Gastroenterology, Cardiology, and dermatology. Company is one of Gliclazide's largest producers and exporters, a medicine to treat type-2 diabetes.

Website BSE NSE
  • Market Cap ₹ 137 Cr.
  • Current Price ₹ 86.2
  • High / Low ₹ 113 / 59.7
  • Stock P/E 20.3
  • Book Value ₹ 65.4
  • Dividend Yield 1.39 %
  • ROCE 9.24 %
  • ROE 6.65 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 4.51% over past five years.
  • Tax rate seems low
  • Company has a low return on equity of 7.62% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
81.97 70.17 92.30 81.49 94.58 73.13 74.70 72.89 81.78 65.64 73.75 87.49 83.92
73.70 63.33 84.64 73.67 85.40 66.57 67.23 64.96 73.95 59.49 67.97 77.82 73.29
Operating Profit 8.27 6.84 7.66 7.82 9.18 6.56 7.47 7.93 7.83 6.15 5.78 9.67 10.63
OPM % 10.09% 9.75% 8.30% 9.60% 9.71% 8.97% 10.00% 10.88% 9.57% 9.37% 7.84% 11.05% 12.67%
0.44 0.45 0.41 0.26 1.85 0.29 0.35 0.51 0.99 0.74 1.13 0.35 -0.22
Interest 3.84 3.64 3.82 3.86 3.34 3.71 4.18 5.02 3.94 4.05 3.86 4.85 4.05
Depreciation 1.66 2.12 2.02 2.55 2.14 2.43 2.12 2.68 2.07 2.52 2.27 3.23 3.04
Profit before tax 3.21 1.53 2.23 1.67 5.55 0.71 1.52 0.74 2.81 0.32 0.78 1.94 3.32
Tax % 33.64% 22.22% 28.25% 25.15% 3.78% 50.70% 21.05% 5.41% -99.29% -0.00% -0.00% -0.00% -11.75%
2.12 1.20 1.60 1.26 5.34 0.36 1.20 0.69 5.61 0.32 0.78 1.95 3.70
EPS in Rs 1.35 0.76 1.02 0.80 3.38 0.23 0.75 0.43 3.52 0.20 0.49 1.22 2.32
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
187 198 226 210 223 171 249 280 303 339 302 311
170 181 206 187 203 164 223 257 277 307 272 279
Operating Profit 18 17 20 23 20 7 27 23 26 32 30 32
OPM % 9% 9% 9% 11% 9% 4% 11% 8% 9% 9% 10% 10%
1 2 3 2 3 4 3 6 2 2 2 2
Interest 7 6 8 9 13 13 12 11 13 15 17 17
Depreciation 7 7 6 7 6 7 7 7 7 10 10 11
Profit before tax 5 5 9 8 4 -9 10 12 9 9 6 6
Tax % 23% 46% 38% 30% -53% -2% 7% 29% 28% 17% -36% -6%
4 3 5 6 7 -9 9 9 6 8 8 7
EPS in Rs 3.12 2.18 3.75 4.19 4.77 -6.28 6.14 5.79 3.91 4.89 4.90 4.24
Dividend Payout % 32% 46% 27% 24% 21% -0% 16% 17% 26% 25% 24% -0%
Compounded Sales Growth
10 Years: 5%
5 Years: 5%
3 Years: 1%
TTM: 3%
Compounded Profit Growth
10 Years: 9%
5 Years: -6%
3 Years: 3%
TTM: -13%
Stock Price CAGR
10 Years: 0%
5 Years: -2%
3 Years: -1%
1 Year: -14%
Return on Equity
10 Years: 7%
5 Years: 8%
3 Years: 8%
Last Year: 7%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 13 13 14 14 14 14 15 15 16 16 16 16
Reserves 43 44 52 58 63 52 64 72 80 77 83 88
49 70 74 91 104 99 104 98 125 134 145 154
59 67 78 88 76 74 78 104 126 108 107 133
Total Liabilities 164 193 219 251 257 239 262 290 348 334 351 391
52 56 60 58 57 56 53 53 63 79 87 94
CWIP 1 4 2 0 0 0 -0 1 -0 0 3 7
Investments 1 1 0 7 7 7 8 8 8 9 5 4
110 132 157 185 193 176 200 227 276 245 256 285
Total Assets 164 193 219 251 257 239 262 290 348 334 351 391

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
14 1 6 13 12 22 10 31 5 29 20 30
-6 -14 -8 -16 -12 -3 -7 -13 -22 -19 -15 -21
-7 12 2 4 0 -20 -3 -17 17 -7 -8 -10
Net Cash Flow 2 -0 0 1 -0 -2 0 -0 0 3 -2 0
Free Cash Flow 9 -13 -2 9 7 18 7 23 -9 18 2 8
CFO/OP 90% 12% 39% 60% 68% 312% 39% 135% 22% 104% 74% 94%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 88 105 99 111 107 110 102 101 114 110 114 113
Inventory Days 132 145 171 240 217 291 146 162 210 167 238 269
Days Payable 142 163 168 183 148 170 118 158 195 148 189 206
Cash Conversion Cycle 78 87 101 168 176 232 130 105 129 129 163 176
Working Capital Days 15 17 38 77 68 55 62 61 61 32 29 30
ROCE % 11% 10% 13% 12% 10% 2% 13% 12% 10% 11% 10% 9%

Insights

In beta
Mar 2015 Mar 2019 Feb 2023 Mar 2024 Jun 2025
Number of Operational Manufacturing Units
Units

Log in to view insights

Please log in to see hidden values.

Login
Total Employee Strength
Number
API Business Order Book
Rs Million
Number of Active API Molecules
Number
Number of Generic Formulations
Number
Doctor Reach
Number
Field Force Size
Number
Formulations Business Order Book
Rs Million
Number of Registrations Worldwide
Number
Total Installed API and Intermediates Capacity
TPA
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
51.61% 51.61% 51.24% 51.24% 51.24% 50.87% 50.87% 50.87% 50.87% 50.87% 50.87% 50.87%
0.17% 0.14% 0.13% 0.13% 0.13% 0.13% 0.14% 0.14% 0.15% 0.23% 0.14% 0.14%
48.23% 48.25% 48.64% 48.64% 48.63% 49.01% 49.00% 49.01% 48.99% 48.91% 49.01% 49.01%
No. of Shareholders 15,86915,52915,06014,77215,01416,00715,66715,72315,82615,77415,52015,214

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls

  • Feb 2023
    Transcript
    AI Summary
    PPT
  • Sep 2022
    Transcript
    AI Summary
    PPT
  • Sep 2022
    Transcript
    AI Summary
    PPT